Recent advances in the path toward the cure for chronic myeloid leukemia

Through the phase 3 International Randomized Study of Interferon vs. STI571 (IRIS) trial, imatinib emerged as the standard treatment for chronic myeloid leukemia (CML) and has successfully prolonged the duration of both the chronic phase (CP) and the disease-free state. The majority of newly diagnos...

Descripción completa

Detalles Bibliográficos
Autor principal: Kim, Dong-Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208199/
https://www.ncbi.nlm.nih.gov/pubmed/22065971
http://dx.doi.org/10.5045/kjh.2011.46.3.169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208199/
https://www.ncbi.nlm.nih.gov/pubmed/22065971
http://dx.doi.org/10.5045/kjh.2011.46.3.169

Ejemplares similares